

Curriculum Vitae

Arman Qamar, MD MPH RPVI FACC

Date Prepared: 08-08-2020

Current Position: Interventional Cardiologist & Vascular Medicine Specialist
NorthShore University Health System
University of Chicago Pritzker School of Medicine
Evanston, IL

Office Address: 2650 Ridge Avenue; Walgreen Building, Floor 3
Evanston, IL 60201

Email: aqamar@northshore.org; aqamar@alumni.harvard.edu

Education

7/03-1/10 M.B, B.S (M.D equivalent)
University College of Medical Sciences, University of Delhi, India
Graduated at the top of university class with Honors & Distinctions

7/18-5/19 MPH in Clinical Effectiveness
Harvard T.H. Chan School of Public Health, Harvard University

Postdoctoral Training

1/10-5/11 Research Fellow, Division of Cardiology
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
(Mentor: Daniel J. Rader, MD)

6/11-6/12 Intern, Department of Medicine, Hospital of the University of Pennsylvania
Philadelphia, PA
(Program Director: Lisa Bellini, MD; Chair: Richard P. Shannon, MD)

6/12-6/14 Resident, Department of Medicine, Hospital of the University of Pennsylvania
Philadelphia, PA
(Program Director: Lisa Bellini, MD; Chair: Richard P. Shannon, MD)

7/14-6/17 Clinical Fellow, Cardiovascular Division, Department of Medicine
Brigham and Women's Hospital, Harvard Medical School, Boston, MA
(Program Director: Donna Polk, MD; Chief: Calum A. MacRae MD, PhD)

7/16-6/17 May Family Vascular Medicine Fellow, Vascular Medicine Section
Cardiovascular Division, Brigham and Women's Hospital
Harvard Medical School, Boston, MA
(Vascular Medicine Section Head: Samuel Z. Goldhaber, MD)

- 7/17-6/19 NIH T32 & Postdoctoral Research Fellow, TIMI Study Group
Brigham and Women's Hospital, Harvard Medical School
(Mentors: Deepak L. Bhatt, MD MPH; Marc S. Sabatine, MD MPH
Eugene Braunwald, MD)
- 7/18-6/19 AHA SFRN Vascular Research Fellow, TIMI Study Group
Brigham and Women's Hospital, Harvard Medical School
(Mentor: Marc P. Bonaca, MD MPH)
- 7/19-6/20 Interventional Cardiology Fellow
New York University Langone Medical Center
(Mentors: Frederick Feit, MD; Craig A. Thompson, MD)

Licensure and Certification

- 8/10 ECFMG (# 0-765-493-2)
- 8/14- American Board of Internal Medicine
- 7/14- Massachusetts Medical License (# 267013)
- 7/16- Federal DEA (#FQ6132548)
- 8/17- National Board of Echocardiography
- 2/19- New York Medical License (#297618)
- 3/19- Certification Board of Nuclear Cardiology
- 9/17- American Board of Internal Medicine- Cardiovascular Medicine
- 3/18- American Board of Vascular Medicine
- 6/19- Registered Physician in Vascular Interpretation (RPVI)
- 5/20- Illinois Medical License (#036.152948)
- 5/20- Illinois Controlled Substance License (#336.113072)

Committee and Board Service

- 7/11-6/14 Intern Selection Committee, Internal Medicine Residency Program
Hospital of the University of Pennsylvania, Philadelphia, PA
- 7/15-6/16 Resident/Fellow Representative, Committee on Interspecialty, Massachusetts
Medical Society
- 8/17-6/19 Next Generation Committee, Society of Vascular Medicine
- 2018-19 Society for Vascular Medicine PAD Tool Kit Committee

Professional Societies

- 2016- Member, American Heart Association (PVD Council)
- 2017- Fellow, Society for Vascular Medicine (FSVM)
- 2020- Member, Society for Cardiovascular Angiography and Interventions (SCAI)
- 2020- Fellow, American College of Cardiology (FACC)

Editorial Activities

Ad Hoc Reviewer

- JAMA
- Circulation
- Journal of the American College of Cardiology
- JACC Cardiovascular Imaging
- Circulation Cardiovascular Outcomes
- American Journal of Cardiology
- Journal of the American Heart Association
- Arteriosclerosis, Thrombosis and Vascular Biology Journal
- Atherosclerosis
- Annals of Internal Medicine
- Canadian Medical Association Journal
- PLOS One Journal
- ACC & AHA Scientific Sessions Abstract Reviewer
- CardioRenal Medicine
- Coronary Artery Disease

Consult Associate Editor, Medscape

Select Clinical Trials Participation

- 7/17-12/18 Co-Investigator, CAMELLIA-TIMI 61 Trial. A randomized trial that examined the cardiovascular safety and efficacy of lorcaserin in 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or risk factors.
- 7/17-6/19 Co- Investigator, HPS-4/TIMI 65 ORION-4 Trial. A randomized controlled trial examining the effects of inclisiran, a small interfering RNA (siRNA) that inhibits the synthesis of PCSK9, on cardiovascular outcomes among 15,000 individuals with atherosclerotic cardiovascular disease.

Select Clinical Registry Participation

- 7/17-6/19 Co-Investigator, Partners Young-MI Registry. A retrospective registry of young Patients with MI across Harvard hospitals.
- 7/19- Co-Principal Investigator, North Indian ST-Segment Elevation Myocardial Infarction Registry. A prospectively multi-center registry evaluating the clinical characteristics, and outcomes of patients with STEMI in India.

Research & Training Grants

- 7/16-6/17 May Family Vascular Medicine Fellowship, Harvard Medical School
100% salary support for clinical & research training in Vascular Medicine
- 7/17-6/19 NIH T32 Postdoctoral Research Training Grant, Harvard Medical School
- *100% salary support for research training at the TIMI Study Group*
 - *100% tuition support for MPH at Harvard University*

- 10/19- NCDR PVI Registry, American College of Cardiology
- *Investigator Initiated-Research Grant*
 - *Funding for Statistical & Research Database Support*
 - *Studying Hospital/Operator Volumes of Peripheral Vascular Intervention & Clinical Outcomes*
 - *Mentor: Deepak L. Bhatt, MD MPH*
- 8/20- Department of Medicine Research Fund; NorthShore University Health System
- *20% salary support for clinical research for 3-years*
 - *Chair of Medicine: John P. Erwin, MD*
 - *Chief of Cardiology: Greg Mishkel, MD MBA*

Report of Local Teaching and Training

- 7/11-6/14 Clinical Teacher to Penn Medical Students
Perelman School of Medicine, University of Pennsylvania
- 7/14-6/19 Clinical Teacher to Harvard Medical Students
Brigham and Women's Hospital
Harvard Medical School
- 2016 Preceptor, Longitudinal Course in Clinical Medicine
Harvard Medical School (2 hours a week for 7 weeks)
- 2017 Preceptor, HST Introduction to Clinical Medicine-Cardiac Exam
Harvard Medical School (Two 2 hour sessions)
- 2018 Preceptor, HST Introduction to Clinical Medicine-Cardiac Exam
Harvard Medical School (2 hours a week for 7 weeks)

Honors and Prizes

- 2005 KS Award, University of Delhi, Awarded for highest marks in Anatomy
- 2005 KS Award, University of Delhi, Awarded for highest marks in Physiology
- 2005 Merit Medal, University of Delhi, Awarded for highest marks in Microbiology
- 2005 Merit Medal, University of Delhi, Awarded for highest marks in Biochemistry
- 2008 Faculty of Pathology Golden Jubilee of Independence Award, University of Delhi
Awarded for highest marks in Pathology
- 2008 KL Award, University of Delhi, Awarded for highest marks in Pharmacology
- 2009 LVP Medal, University of Delhi, Awarded for highest marks in Obstetrics
- 2010 Deans Gold Medal, University of Delhi, Awarded for first position in medical school class

- 2010 Delhi Medical Association Gold Medal, University of Delhi, Awarded for first position in medical school class
- 2010 Medical School Alumni Award, University of Delhi, Awarded for academic excellence
- 2010 Memorial Gold Medal, University of Delhi, Awarded for highest marks in Internal Medicine
- 2010 MS Award & CB Gold Medal, University of Delhi, Awarded for highest marks in Internal Medicine
- 2010 SR Gold Medal, University of Delhi, Awarded for highest marks in Surgery
- 2010 Dr A. M. Memorial Award, University of Delhi, Awarded for first position in the fourth year of medical school
- 2010 LHSJ Memorial Medal, University of Delhi, Awarded for first position in the fourth year of medical school
- 2010 RV Gold Medal, University of Delhi, Awarded for academic excellence in medical school
- 2010 Dr KKSM Gold Medal, University of Delhi, Awarded in recognition of academic excellence in medical school
- 2010 S Vishwanathan Prize, University of Delhi, Awarded for highest marks in Obstetrics and Gynaecology
- 2010 PCC Memorial Prize, University of Delhi, Awarded for academic excellence in medical school
- 2013 The Maurice F. Attie Junior Resident Teaching Award
Department of Medicine, Perelman School of Medicine, University of Pennsylvania
- 2013 Frederick F. Samaha Award for Resident Scholarship
Department of Medicine, Perelman School of Medicine, University of Pennsylvania
- 2014 The Maurice F. Attie Senior Resident Teaching Award
Department of Medicine, Perelman School of Medicine, University of Pennsylvania
- 2015 Fellow Teaching Award. Division of Cardiology
Department of Medicine. Brigham and Women's Hospital, Harvard Medical School
- 2015 Russek Travel Award, American College of Cardiology
- 2016 Travel Award, VIVA, Las Vegas (Vascular Interventional Advances Conference)

- 2018 Eugene Braunwald Fellowship Award in Cardiovascular Medicine
Brigham and Women's Hospital (BWH), Harvard Medical School
- Awarded to 1 fellow for excellence in clinic research at BWH
- 2018 Finalist, Young Investigator Award, Society for Vascular Medicine
- 2018 Finalist, Young Investigator Award, Northwestern Young Investigator CV Forum
- 2019 Young Investigator Award, American Association of Cardiologist of Indian Origin

Peer-Reviewed Publications

1. **Qamar A**, Bangalore S. Beta-Blocker Therapy After Myocardial Infarction: Is There an Expiry Date? Can J Cardiol. 2020 Apr 11:S0828-282X(20)30389-5.
2. Bhatia K, Uberoi G, Bajaj NS, Jain V, Arora S, Tafur A, Bangalore S, Olin JW, Piazza G, Goldhaber SZ, Vaduganathan M, **Qamar A**. Meta-analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients with Cancer. American Journal of Cardiology. 2020. In Press
3. **Qamar A**, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP. Effect of Vorapaxar on Cardiovascular and Limb Outcomes in Patients with Peripheral Artery Disease with and without Coronary Artery Disease: Analysis from TRA 2°P-TIMI 50 Trial. Vasc Med. 2020 Apr;25(2):124-132.
4. Gupta MD, Gupta P, Mp G, Roy A, **Qamar A**. Risk factors for myocardial infarction in very young South Asians. Curr Opin Endocrinol Diabetes Obes. 2020 Apr;27(2):87-94.
5. Byrne C, Pareek M, Vaduganathan M, Biering-Sørensen T, **Qamar A**, Pandey A, Olesen TB, Olsen MH, Bhatt DL. Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. Eur Heart J Cardiovasc Pharmacother. 2019 Sep 14:pvz050.
6. Ujjawal A, Gupta M, Ghosh RK, Jain V, Bandyopadhyay D, **Qamar A**, Aronow WS, Deedwania P, Kapadia S, Lavie CJ. Aspirin for Primary Prevention of Coronary Artery Disease. Curr Probl Cardiol. 2020 Feb 14:100553.
7. **Qamar A**, Antman EM, Giugliano RP. Reply: Anticoagulants in Atrial Fibrillation and Liver Disease. J Am Coll Cardiol. 2019 Nov 12;74(19):2436-2437.
8. Singh A, Gupta A, DeFilippis EM, **Qamar A**, Biery DW, Almarzooq Z, Collins B, Fatima A, Jackson C, Galazka P, Ramsis M, Pipilas DC, Divakaran S, Cawley M, Hainer J, Klein J, Jarolim P, Nasir K, Januzzi JL, Di Carli MF, Bhatt DL, Blankstein R. Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults. J Am Coll Cardiol. 2020 Mar 10;75(9):1003-1013.

9. Gupta P, Arora S, **Qamar A**, Gupta M, Seth A. Current status of transcatheter aortic valve replacement in India. *Cardiovasc Diagn Ther.* 2020 Feb;10(1):83-88.
10. Divakaran S, Singh A, Biery D, Yang J, DeFilippis EM, Collins BL, Ramsis M, **Qamar A**, Hainer J, Klein J, Cannon CP, Polk DM, Plutzky J, Nasir K, Januzzi JL, Di Carli MF, Bhatt DL, Blankstein R. Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. *Diabetes Care.* 2020 Aug;43(8):1843-1850.
11. Mahabir CA, DeFilippis EM, Aggarwal S, Bath A, **Qamar A**, Patel NK, Goldsweig AM, Vaduganathan M. The First 4 Years of Postmarketing Safety Surveillance Related to the MitraClip Device: A United States Food and Drug Administration MAUDE Experience. *J Invasive Cardiol.* 2020 May;32(5):E130-E132.
12. Pandey A, Vaduganathan M, Arora S, **Qamar A**, Mentz RJ, Shah SJ, Chang PP, Russell SD, Rosamond WD, Caughey MC. Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. *Circulation.* 2020 Jul 21;142(3):230-243.
13. **Qamar A**, Bangalore S. Biomarkers to Personalize Preoperative Cardiovascular Risk Stratification: Ready for Prime Time? *Annals of Internal Medicine.* 2019 (In Press).
14. **Qamar A**, Giugliano RP, Bohula EA, Park JG, Jarolim P, Blazing M, Califf R, Cannon CP, Braunwald E, Morrow DA. Biomarkers, Cardiovascular Outcomes, and the Clinical Benefit of Ezetimibe: An Analysis from IMPROVE-IT. *J Am Coll Cardiol.* 2019 Aug 27; 74(8):1057-1068.
15. **Qamar A**, Antman E, Ruff C, Nordio F, Murphy S, Grip LT, Greenberger N, Yin O, Choi Y, Lanz H, Mercuri M, Braunwald E, Giugliano RP. Edoxaban versus Warfarin in Patients with Atrial Fibrillation and History of Liver Disease. *J Am Coll Cardiol.* 2019 Jul 16; 74(2):179-189.
16. Khetarpal SA, **Qamar A**, Bick AG, Fuster JJ, Kathiresan S, Jaiswal S, Natarajan P. Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD. *J Am Coll Cardiol.* 2019 Jul 22; 74(4): 578-586.
17. **Qamar A**, Libby P. Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go? *Curr Cardiol Rep.* 2019 Jun 27; 21(8):77.
18. Arora S*, **Qamar A***, Gupta P, Vaduganathan M, Chauhan I, Tripathi AK, Sharma VY, Bansal A, Fatima A, Jain G, Batra V, Tyagi S, Khandelwal L, Kaul P, Rao SV, Girish MP, Bhatt DL, Gupta MD. Design and rationale of the North Indian ST-Segment Elevation Myocardial Infarction Registry: A prospective cohort study. *Clin Cardiol.* 2019; 1-7. In Press (*Authors contributed equally as co-first authors).
19. Jogu HR, Arora S, Strassle PD, Patel C, Patil N, Venkatesh S, Alkhamy H, Ramm CJ, **Qamar A**, Kim SM, Yeung M, Vavalle JP. Impact of age and comorbidities on the effect of transcatheter versus surgical mitral valve repair on inpatient outcomes. *Catheter Cardiovasc Interv.* 2019 Sep 2.

20. Jha MK, **Qamar A**, Vaduganathan M, Charney DS, Murrough JW. Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2019 Apr 16;73(14):1827-1845
21. **Qamar A**, Libby P, Bhatt DL. Targeting RNA to lower triglycerides: long strides from short molecules. *Eur Heart J*. 2019 May 15. Pii: ehz321.
22. Patil N, Arora S, **Qamar A**, Strassle PD, Alexander KM, Fatima A, Maurer MS, Grodin JL, Pandey A. Trends and causes of hospitalizations in patients with amyloidosis. *Amyloid*. 2019 Jun 7:1-2.
23. Arora S, Shemisa K, Vaduganathan M, **Qamar A**, Gupta A, Garg SK, Kumbhani DJ, Mayo H, Khalili H, Pandey A, Das SR. Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019 May 21; 73(19):2454-2464.
24. Singh A, Gupta A, Collins BL, **Qamar A**, Monda KL, Biery D, Lopez JAG, de Ferranti SD, Plutzky J, Cannon CP, Januzzi JL Jr, Di Carli MF, Nasir K, Bhatt DL, Blankstein R. Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. *J Am Coll Cardiol*. 2019 May 21; 73(19):2439-2450.
25. **Qamar A**, Giugliano RP, Sabatine MS. Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply. *JAMA Cardiol*. 2019 May 1.
26. Arora S, Cavender MA, Chang PP, **Qamar A**, Rosamond WD, Hall ME, Rossi JS, Kaul P, Caughey MC. Outcomes of decreasing versus increasing cardiac troponin in patients admitted with non-ST-segment elevation myocardial infarction: the Atherosclerosis Risk in Communities Surveillance Study. *Eur Heart J Acute Cardiovasc Care*. 2019 Apr 8. Epub ahead of print.
27. **Qamar A**, Giugliano RP, Keech AC, Kuder JF, Murphy SA, Kurtz CE, Wasserman SM, Sever PS, Pedersen TR, Sabatine MS. Interindividual Variation in LDL-C Reduction With Evolocumab: An Analysis of FOURIER Data. *JAMA Cardiol*. 2019 Jan 1;4(1):59-63
28. **Qamar A**, Braunwald E. Treatment of Hypertension: Addressing a Global Health Problem. *JAMA*. 2018 Nov 6; 320(17):1751-1752.
29. **Qamar A**, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral Anticoagulation in Patients With Liver Disease. *J Am Coll Cardiol*. 2018 May 15;71(19):2162-2175
30. Jogu HR, Arora S, Vaduganathan M, **Qamar A**, Pandey A, Chevli PA, Pansuriya TH, Ahmad MI, Dutta A, Sunkara PR, Qureshi W, Vasu S, Upadhyaya B, Bhatt DL, Januzzi JL Jr, Herrington D. Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry. *Clin Cardiol*. 2019 Jun; 42(6):592-604.
31. Vaduganathan M, Patel RB, Singh A, McCarthy CP, **Qamar A**, Januzzi JL Jr, Scirica BM, Butler J, Cannon CP, Bhatt DL. Prescription of Glucagon-Like Peptide-1

- Receptor Agonists by Cardiologists. *J Am Coll Cardiol*. 2019 Apr 2; 73(12):1596-1598.
32. Mosarla RC, Vaduganathan M, **Qamar A**, Moslehi J, Piazza G, Giugliano RP. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019 Mar 26; 73(11):1336-1349.
 33. Droppa M, Vaduganathan M, Venkateswaran RV, Singh A, Szumita PM, Roberts RJ, **Qamar A**, Hack L, Rath D, Gawaz M, Fuernau G, de Waha-Thiele S, Desch S, Schneider S, Ouarrak T, Jaffer FA, Zeymer U, Thiele H, Bhatt DL, Geisler T. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. *Resuscitation*. 2019 Apr; 137: 205-212.
 34. Pareek M, Vaduganathan M, Biering-Sørensen T, Byrne C, **Qamar A**, Almarzooq Z, Pandey A, Olsen MH, Bhatt DL. Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT). *Am J Med*. 2019 Jun; 132(6):733-739.
 35. Scirica BM, Bohula EA, Dwyer JP, **Qamar A**, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee and Investigators. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. *Circulation*. 2019 Jan 15; 139(3):366-375.
 36. Arora S, Stouffer GA, Kucharska-Newton AM, **Qamar A**, Vaduganathan M, Pandey A, Porterfield D, Blankstein R, Rosamond WD, Bhatt DL, Caughey MC. Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction. *Circulation*. 2019 Feb 19; 139(8):1047-1056.
 37. Arora S, Strassle PD, **Qamar A**, Kolte D, Pandey A, Paladugu MB, Borhade MB, Ramm CJ, Bhatt DL, Vavalle JP. Trends in Inpatient Complications After Transcatheter and Surgical Aortic Valve Replacement in the Transcatheter Aortic Valve Replacement Era. *Circ Cardiovasc Interv*. 2018 Nov; 11(11):e007517.
 38. DeFilippis EM, Singh A, Gupta A, Ayuba G, Biery D, Divakaran S, Collins BL, **Qamar A**, Fatima A, Hainer J, Klein J, Nasir K, Di Carli MF, Bhatt DL, Blankstein R. Long-Term Outcomes After Out-of-Hospital Cardiac Arrest in Young Patients With Myocardial Infarction. *Circulation*. 2018 Dec 11; 138(24):2855-2857.
 39. Vaduganathan M, Sathiyakumar V, Singh A, McCarthy CP, **Qamar A**, Januzzi JL Jr, Scirica BM, Butler J, Cannon CP, Bhatt DL. Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. *J Am Coll Cardiol*. 2018 Dec 25; 72(25):3370-3372.

40. Arora S, Stouffer GA, Kucharska-Newton A, Vaduganathan M, **Qamar A**, Matsushita K, Kolte D, Reynolds HR, Bangalore S, Rosamond WD, Bhatt DL, Caughey MC. Fifteen-Year Trends in Management and Outcomes of Non-ST-Segment-Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community Surveillance Study, 2000-2014. *J Am Heart Assoc.* 2018 Oct 2; 7(19):e010203.
41. Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, **Qamar A**, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM; CAMELLIA-TIMI 61 Steering Committee and Investigators. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. *N Engl J Med.* 2018 Sep 20; 379(12):1107-1117.
42. Golwala HB, Cannon CP, Steg PG, Doros G, **Qamar A**, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DL. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. *Eur Heart J.* 2018 May 14; 39(19):1726-1735.
43. Arora S, Strassle PD, **Qamar A**, Wheeler EN, Levine AL, Misenheimer JA, Cavender MA, Stouffer GA, Kaul P. Impact of Type 2 Myocardial Infarction (MI) on Hospital-Level MI Outcomes: Implications for Quality and Public Reporting. *J Am Heart Assoc.* 2018 Mar 26; 7(7). Pii: e008661.
44. DeFilippis EM, Singh A, Divakaran S, Gupta A, Collins BL, Biery D, **Qamar A**, Fatima A, Ramsis M, Pipilas D, Rajabi R, Eng M, Hainer J, Klein J, Januzzi JL, Nasir K, Di Carli MF, Bhatt DL, Blankstein R. Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction. *J Am Coll Cardiol.* 2018 Jun 5; 71(22):2540-2551.
45. Vaduganathan M, Pareek M, **Qamar A**, Pandey A, Olsen MH, Bhatt DL. Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT. *Am J Med.* 2018 Aug; 131(8):956-960.
46. Gupta A, Bajaj NS, Arora P, Arora G, **Qamar A**, Bhatt DL. FFR-guided Multivessel Stenting Versus Infarct-Related Artery Only Stenting in ST-Elevation Myocardial Infarction: A Meta-analysis of Randomized Controlled Trials. *Int J Cardiol.* 2018 Feb 1; 252:63-67.
47. Vaduganathan M, **Qamar A**, Gupta A, Bajaj N, Golwala HB, Pandey A, Bhatt DL. Percutaneous Closure of Patent Foramen Ovale for Secondary Prevention of Cryptogenic Stroke: An Updated Meta-Analysis of Randomized Clinical Trials. *Am J Med.* 2018 May; 131(5):575-577.
48. Vaduganathan M, **Qamar A**, Badreldin HA, Faxon DP, Bhatt DL. Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock. *JACC Cardiovasc Interv.* 2017 Dec 11;10(23):2468-2469.

49. Singh A, Collins BL, Gupta A, Fatima A, **Qamar A**, Biery D1, Baez J, Cawley M, Klein J, Hainer J, Plutzky J, Cannon CP, Nasir K, Di Carli MF, Bhatt DL, Blankstein R. Cardiovascular Risk and Statin Eligibility of Young Adults After an Myocardial Infarction: Partners YOUNG-MI Registry. *J Am Coll Cardiol*. 2018 Jan 23; 71(3):292-302.
50. Vaduganathan M, Nagarur A, **Qamar A**, Patel RB, Navar AM, Peterson ED, Bhatt DL, Fonarow GC, Yancy CW, Butler J. Availability and Use of Shared Data from Cardiometabolic Clinical Trials. *Circulation*. 2018 Feb 27; 137(9):938-947.
51. Agarwal N, Mahmoud AN, Patel NK, Jain A, Garg J, Mojadidi MK, Agrawal S, **Qamar A**, Golwala H, Gupta T, Bhatia N, Anderson RD, Bhatt DL. Meta-Analysis of Aspirin Versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. *Am J Cardiol*. 2018 Jan 1;121(1):32-40.
52. Vaidya SR, **Qamar A**, Arora S, Devarapally SR, Kondur A, Kaul P. Culprit versus multivessel coronary intervention in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. *Coron Artery Dis*. 2017 Nov 8. *Coron Artery Dis*. 2018 Mar; 29(2):151-160.
53. Wu C, Singh A, Collins B, Fatima A, **Qamar A**, Gupta A, Hainer J, Klein J, Jarolim P, Di Carli M, Nasir K, Bhatt DL, Blankstein R. Causes of Troponin Elevation and Associated Mortality in Young Patients. *Am J Med*. 2018 Jan 10. pii: S0002-9343(17)31102-6.
54. Vaduganathan M, **Qamar A**, Aragam K. Preparing Fellows for Precision Cardiology: Are We Ready? *J Am Coll Cardiol*. 2017 Sep 26; 70(13):1675-1679.
55. Vaduganathan M, **Qamar A**, Badreldin HA, Faxon DP, Bhatt DL. Cangrelor Use in Cardiogenic Shock: A Single-Center Real-World Experience. *JACC Cardiovasc Interv*; 2017, Aug; 10(16): 1712-1714.
56. Singh A, Collins B, **Qamar A**, Gupta A, Fatima A, Divakaran S, Klein J, Hainer J, Jarolim P, Shah RV, Nasir K, Di Carli MF, Bhatt DL, Blankstein R. Study of young patients with myocardial infarction: Design and rationale of the YOUNG-MI Registry. *Clin Cardiol*. 2017 Nov; 40(11):955-961.
57. Pareek M, Bhatt DL, Vaduganathan M, Biering-Sørensen T, **Qamar A**, Diederichsen AC, Møller JE, Hindersson P, Leósdóttir M, Magnusson M, Nilsson PM, Olsen MH. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. *Eur J Prev Cardiol*; 2017, Oct; 24(15): 1648-1659.
58. Badreldin HA, Carter D, Cook BM, **Qamar A**, Vaduganathan M, Bhatt DL. Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention. *Am J Cardiol*. 2017 Aug 1; 120(3):359-361.

59. Arora SM, Matsushita K, **Qamar A**, Stacey RB, Caughey MC. Early versus Late Percutaneous Revascularization in Patients Hospitalized with Non ST-Segment Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Surveillance Study. *Catheter Cardiovasc Interv.* 2018 Feb 1; 91(2):253-259.
60. Vaduganathan M*, **Qamar A***, Singh A, Venkateswaran R, Szumita P, Croce K, Mauri L, Leopold J, Shah P, Sobieszczyk P, Faxon D, Bhatt DL. Cangrelor Use Since FDA Approval: A Single-Center Real-World Experience at a Tertiary Care Hospital. *J Am Coll Cardiol.* 2017 Jan 31; 69(4):463-464. (* Authors contributed equally to this work)
61. **Qamar A**, Bhatt DL. Optimizing the Use of Cangrelor in the Real World. *Am J Cardiovasc Drugs.* 2017 Feb; 17(1):5-16.
62. Vaduganathan M, Kornowski R, **Qamar A**, Greenberg G, Bental T, Rechavia E, Lev EI, Vaknin-Assa H, Assali AR. One-Year Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Varying Quantities of Coronary Artery Calcium (from a 13-Year Registry). *Am J Cardiol.* 2016; 118(8): 1111-1116.
63. Khetarpal SA, **Qamar A**, Millar JS, Rader DJ. Targeting ApoC-III to Reduce Coronary Disease Risk. *Curr Atheroscler Rep.* 2016; 18(9):54.
64. Alexander KM, Vaduganathan M, **Qamar A**, Gerhard-Herman MD. Grim Messenger: Virchow's Node Presenting with Virchow's Triad. *Am J Med.* 2016; 129(9):948-51.
65. **Qamar A**, Veeranna V, Fatima A, Alexander KM, Di Carli MF, Bonaca MP, Steigner M, Dorbala S. Utility of multimodality imaging in myopericarditis with aortitis. *J Nucl Cardiol.* 2017 Jun; 24(3):1103-1106.
66. Dahagam C, Goud A, Abdelgader A, Hendrani A, Feinstein MJ, **Qamar A**, Joshi PH, Swiger KJ, Byrne K, Quispe R, Jones SR, Blumenthal RS, Martin SS. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab. *Future Cardiol.* 2016; 12(2):149-157.
67. Dahagam C, Goud A, Abdelgader A, Hendrani A, Feinstein MJ, **Qamar A**, Joshi PH, Swiger KJ, Byrne K, Quispe R, Jones SR, Blumenthal RS, Martin SS. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. *Future Cardiol.* 2016; 12(2):139-148.
68. **Qamar A**, Bhatt DL. Current status of data on cangrelor. *Pharmacology and Therapeutics.* 2016. *Pharmacol Ther.* 2016; 159:102-109.
69. **Qamar A**, Bhatt DL. Stroke Prevention in Atrial Fibrillation in Patients with Chronic Kidney Disease. *Circulation.* 2016; 133(15):1512-5.
70. **Qamar A**, Bhatt DL. Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels: Just a Theory or Real Concern? *Circ Res.* 2015; 117(8):662-4.

71. **Qamar A**, Bhatt DL. Culprit-Only vs. Complete Revascularization during ST-Segment Elevation Myocardial Infarction. *Prog Cardiovasc Dis.* 2015; 58(3): 260-6.
72. **Qamar A***, Khetarpal SA*, Khera AV, Qasim A, Rader DJ, Reilly MP. Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 Diabetics. *Arterioscler Thromb Vasc Biol.* 2015; 35(8):1880-8. (*Authors contributed equally to this work).
73. Khera AV, **Qamar A**, Murphy SA, Cannon CP, Sabatine MS, Rader DJ. On-Statins, Resistin, Leptin, and Risk of Recurrent Coronary Events after Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study). *Am J Cardiol.* 2015; 116(5):694-8.
74. AV Khera, **A Qamar**, MP Reilly, RL Dunbar, DJ Rader; Effects of niacin, statin, and fenofibrate on circulating PCSK9 levels in patients with dyslipidemia. *Am J Cardiol.* 2015; 115(2):178-82.
75. **Qamar A**, Siddiqi HK, Rossman MD. Worth a Second Look. A 49-Year-Old Woman with Progressive Dyspnea. *Ann Am Thorac Soc.* 2015; 12(7):1093-6.
76. **Qamar A**, Bhatt DL. Reply: Warfarin in patients on haemodialysis with atrial fibrillation—friend or foe? *Nat Rev Nephrol.* 2015; 11(8):450.
77. **Qamar A**, Bhatt DL. Anticoagulation therapy: Balancing the risks of stroke and bleeding in CKD. *Nat Rev Nephrol.* 2015; 11(4):200-2.
78. Mehta N, **Qamar A**, Qu L, Qasim AN, NN Mehta, Reilly MP, Rader DJ. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits. *Arterioscler Thromb Vasc Biol.* 2014; 34(5):1057-63.
79. Usman MH, **Qamar A**, Gadi R, Lilly S, Goel H, Hampson J, Mucksavage ML, Nathanson GA, Rader DJ, Dunbar RL. Extended-Release Niacin Acutely Suppresses Postprandial Triglyceridemia. *American Journal of Medicine.* 2012; 125(10): 1026-1035.
80. **Qamar A**, Ioannides KL, Khetarpal S, Kiss D. Bilateral Earlobe Creases and Severe Coronary Artery Disease. *Circulation.* 2014; 130(1): 92-3.
81. **Qamar A**, Rader DJ. Effect of Interleukin 1 Beta Inhibition in Cardiovascular Disease. *Current Opinion in Lipidology.* 2012; 23(6): 548-553.
82. Aggarwal S, **Qamar A**, Sharma V, Sharma A. Abdominal Aortic Aneurysm: A Comprehensive Review. *Experimental and Clinical Cardiology.* 2011; 16(1): 11-15.

Peer Reviewed Book Chapters

1. **Qamar A**, Scirica B. (2019). Management of Acute Coronary Syndrome. In Robert Hyzy MD (Ed.), Hyzy/ Evidence Based Critical Care: A Case Study Approach. Springer Science and Business Media. (Author).
2. **Qamar A**, Kotha KS, Ioachimescu OC. (2011). Obstructive Sleep Apnea. In Octavian C Ioachimescu M.D (Ed.), Contemporary Sleep Medicine for Physicians (pp. 71-110). Oak Park, IL, USA: Bentham Science Publisher. (Author).

Invited Lectures or Grand Rounds

1. Invited Speaker and Panel Discussant. American College of Cardiology Rise and Shine Series: Just the Facts – An Objective Overview of PCSK9 Inhibitors. Miami, FL. May 2015. Program Chairs: Robert Bonow, MD MACC; William Dec, MD, FACC.
2. Invited Speaker and Panel Discussant. American College of Cardiology Rise and Shine Series: Just the Facts – An Objective Overview of PCSK9 Inhibitors. Chicago, IL. June 2015. Program Chairs: Robert Bonow, MD MACC; William Dec, MD, FACC.
3. Invited Speaker. Pfizer Venous Thromboembolism Symposium. Boston, MA. December 2016.
4. Invited Speaker. Challenging the Standard of Care. Emerging Concepts in VTE Treatment and Prevention. 66th Annual Scientific Session of the American College of Cardiology. Washington DC. March 2017. Program Chairs: Gregory Piazza, MD; Geoffrey Barnes, MD.
5. Invited Speaker and Panel Discussant. Assessing VTE Risk in Medically Ill Patients. The Critical Role of the Hospitalist. Medscape Education: Society of Hospital Medicine Annual Conference. Las Vegas, May 2017.
6. Invited Speaker. LDL-Cholesterol Lowering in Atherosclerotic Cardiovascular Disease: Past, Present, and Future. Department of Medicine Grand Rounds. Loyola University Medical Center. Maywood, IL, March 2020.
7. Invited Speaker. Anti-Thrombotic Therapy in Patients with Atrial Fibrillation Undergoing PCI. Cardiology Grand Rounds. Loyola University Medical Center. Maywood, IL, March 2020.